TD Cowen lowered the firm’s price target on Lyft (LYFT) to $14 from $16 and keeps a Hold rating on the shares. The firm said 4Q GBs were 1.0% ...
TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...
Teledyne Technologies Incorporated (NYSE:TDY) today announced that George Bobb, President and Chief Operating Officer, and Jason VanWees, Vice Chairman, will present at the TD Cowen 46th Annual ...
TD Cowen analyst William Katz maintained a Hold rating on Artisan Partners (APAM – Research Report) today and set a price target of $46.00. The ...
Canada’s telecom sector has been under pressure, but is the operating environment beginning to improve? TD Cowen's Vince ...
Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...
TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...
Salesforce has been upgraded to a Buy from TD Cowen analysts, who also raised their price target to $400 per share citing the year-end stock rally tied to the deployment of the Agentforce AI product ...
TD Cowen analyst William Katz maintained a Buy rating on Invesco (IVZ – Research Report) today and set a price target of $22.00. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback